Stephen Stahl - Future of Psychopharmacology - Is New Treatment Innovation “Dead”?

Watch on LabRoots at labroots.com/webcast/id/816
Adjunct Professor of Psychiatry, University of California, San Diego, Honorary Visiting Senior Fellow, University of Cambridge, UK, Chairman, Neuroscience Education Institute (NEI), Editor-in Chief, CNS Spectrums, Director of Psychopharmacology Services, California Department of State Hospitals
Innovation in Psychopharmacology is Dead. Long Live Innovation in Psychopharmacology!
What’s going on in our field?
Priorities of Big Pharma shifting away from CNS and especially from psychiatry
Failed clinical trials littering the landscape
Even known drugs don’t work in psychiatric trials
Broken clinical trial apparatus
Iterative step-wise improvements or ‘me-too’ agents not reimbursed
Aggressive cost controls
No new validated targets
Learning objectives -
Discuss the reasons for the slow down of innovative new treatments entering psychopharmacology and the exit of Big Pharma largely from psychiatry
Show that future advances may be based on targeting symptoms that cut across a large array of psychiatric disorders
Propose that effective new treatments will be based upon subpopulations defined mostly in the short run by symptoms but in the long run by genetic and imaging biomarkers

[@greggl.friedmanmd7512]

Very interesting lecture by Stephen M. Stahl MD. Thank you for posting this lecture video. By Gregg L. Friedman MD

[@christinecochran5215]

Although this is dated March, 2016, please note that the NEI slide deck has 2012 as the copyright year. :)

[@naseralriyami2568]

Thank you for noting that the slide deck is dated back to 2012
I’ve learnt a lot! And I’m looking forward to learning from Dr Stahl in the upcoming mental health conference in Abu Dhabi!
Psychiatric disorders are not only produced by “bad” genes; they’re also produced by “normal” genes.
In psychiatry, symptom suppression doesn’t mean the same thing as it does in other areas of medicine. In psychiatry, the symptom may be the disease and symptom suppression may both improve function and prevent disease progression.
We don’t need first line drugs; we need drugs for treatment resistance. First line treatments have already been satisfied through other elements of an MDT service. We resort to drugs when first line treatments don’t work.
The future targets of drug interventions lies in affecting changes in cognition, substance abuse and inflammatory and immune dysregulation.
Innovation is not dead in psychopharcotherapy. We’re changing The methodologies are changing. New problems are being addressed and the new targets are neurocircuitry underlying symptoms shared by different psychiatric disorders.

[@christinecochran5215]

@@naseralriyami2568 oh I'm a lay person but I'm a huge huge fan of Dr S. Stahl!!

[@katherinereinleitner3644]

This is one of the best lectures in this series. Thank you Dr. Stahl.

[@simaayoubi5121]

I appreciate the information you have shared .

[@robertorodriguez-jimenez1330]

Great Stephen!

[@JABDUDE]

what is meant by "information processing efficiency" ?

[@dylan111112]

A true genius...the godfather of psychopharmacology